Stockscreener 앱 받기
1.53
8.93%
-0.15
시간 외 거래:
1.58
0.05
+3.27%
전일 마감가:
$1.68
열려 있는:
$1.68
하루 거래량:
151.30K
Relative Volume:
0.06
시가총액:
$43.48M
수익:
-
순이익/손실:
$-87.23M
주가수익비율:
-0.5152
EPS:
-2.97
순현금흐름:
$-82.77M
1주 성능:
+15.04%
1개월 성능:
+1.32%
6개월 성능:
-80.08%
1년 성능:
-86.92%
1일 변동 폭
$1.515
$1.68
1주일 범위
$1.28
$1.78
52주 변동 폭
$0.8801
$19.30
Pepgen Inc Stock (PEPG) Company Profile
명칭
Pepgen Inc
전화
703-456-8000
주소
1 MARINA PARK DRIVE, SUITE 900, BOSTON
PEPG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.53 | 43.48M | 0 | -87.23M | -82.77M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-07-31 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-21 | 개시 | H.C. Wainwright | Buy |
Pepgen Inc 주식(PEPG)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - Bluefield Daily Telegraph
PepGen Inc. CEO Makes Bold Stock Purchase! - TipRanks
Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
PepGen Inc.’s CEO Makes Bold Stock Purchase! - TipRanks
PepGen president and CEO McArthur buys shares worth $47,724 By Investing.com - Investing.com Canada
PepGen president and CEO McArthur buys shares worth $47,724 - Investing.com
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
PepGen stock plunges to 52-week low of $1.14 amid market challenges - Investing.com Canada
PepGen stock plunges to 52-week low of $1.14 amid market challenges By Investing.com - Investing.com South Africa
PepGen (NASDAQ:PEPG) Stock Price Down 14.4% – Time to Sell? - Defense World
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
PepGen Announces Appointment of Two New Directors to its Board - BioSpace
PepGen Appoints Lisa Wyman and Mitchell Finer to its Board of Directors - citybiz
PepGen Inc. Expands Board with New Appointments - TipRanks
PepGen names two new directors to board - TipRanks
PepGen CMO Mellion resigns, effective April 4 - Investing.com Australia
PepGen CMO Mellion resigns, effective April 4 By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen IncPEPG - Bluefield Daily Telegraph
PEPG ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of PepGen Inc. Shareholders Who Lost Money - ACCESS Newswire
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
PepGen Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsPEPG - ACCESS Newswire
PepGen Inc. Faces Clinical Trial Challenges and Competitive Pressures Leading to Sell Rating - TipRanks
What Do Analysts Think Will Happen To PepGen Inc (NASDAQ: PEPG) - Stocks Register
PepGen to Participate in Upcoming March 2025 Investor Conferences - BioSpace
PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls - Benzinga
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD - Marketscreener.com
Boston biotech's stock drops after Duchenne trial pause - The Business Journals
PepGen to pause CONNECT2-EDO51 study - TipRanks
PepGen slumps after pausing mid-stage study of Duchenne drug - TradingView
PepGen pauses phase 2 DMD study to review earlier trial data - Investing.com India
Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD -March 04, 2025 at 08:18 am EST - Marketscreener.com
PepGen stock slides after trial pause (PEPG:NASDAQ) - Seeking Alpha
Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD - TradingView
PepGen to Participate in Upcoming Investor Conferences - Business Wire
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz? - Asianet Newsable
PepGen (PEPG) to Release Quarterly Earnings on Wednesday - Defense World
PEPG Stock Price and Chart — NASDAQ:PEPG - TradingView
Pepgen Inc (PEPG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):